Skip to main content
Top
Published in: Surgery Today 1/2019

01-01-2019 | Original Article

Meaning of C-reactive protein around esophagectomy for cStage III esophageal cancer

Authors: Yasunori Otowa, Tetsu Nakamura, Yuta Yamazaki, Gosuke Takiguchi, Akio Nakagawa, Masashi Yamamoto, Shingo Kanaji, Takeru Matsuda, Taro Oshikiri, Satoshi Suzuki, Yoshihiro Kakeji

Published in: Surgery Today | Issue 1/2019

Login to get access

Abstract

Purpose

The prognosis of esophageal cancer is dismal, and the 3-year overall survival of cStage III does not reach 50.0%. C-reactive protein (CRP) is a well-known protein that reflects the short- and long-term operative outcomes of esophageal cancer. However, since elevated CRP levels are often observed in cStage III esophageal cancer, whether or not CRP still reflects the prognosis is unclear.

Methods

Eighty-four patients who were diagnosed with cStage III esophageal cancer and underwent R0/1 operation from January 2007 to December 2014 were retrospectively evaluated.

Results

The mean age was 66.8 years, and the majority of patients were male. The median preoperative and postoperative CRP levels were 0.15 and 1.47 mg/dl, respectively. A majority of the patients underwent thoracoscopic surgery, and the median blood loss and operation duration were 456 ml and 11.6 h, respectively. Forty-six patients (54.8%) died during the observation period, and the 3-year overall survival was 52.4%. A multivariate analysis showed that the preoperative CRP level, postoperative albumin level, blood loss, and complications were independent prognostic factors. A multiple linear regression analysis showed that an elevated postoperative CRP level was affected by the operation duration and preoperative CRP levels.

Conclusions

These findings suggest that the preoperative CRP level is a prognostic factor for cStage III esophageal cancer and that postoperative elevation in the CRP level is affected by the operation duration.
Literature
1.
go back to reference Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
2.
go back to reference Tachimori Y, Ozawa S, Numasaki H, Ishihara R, Matsubara H, Muro K, et al. The Registration Committee for Esophageal Cancer of the Japan Esophageal Society. Comprehensive Registry of Esophageal Cancer in Japan. Esophagus. 2017;14:189–214.CrossRef Tachimori Y, Ozawa S, Numasaki H, Ishihara R, Matsubara H, Muro K, et al. The Registration Committee for Esophageal Cancer of the Japan Esophageal Society. Comprehensive Registry of Esophageal Cancer in Japan. Esophagus. 2017;14:189–214.CrossRef
3.
go back to reference Okamura A, Takeuchi H, Matsuda S, Ogura M, Miyasho T, Nakamura R, et al. Factors affecting cytokine change after esophagectomy for esophageal cancer. Ann Surg Oncol. 2015;22:3130–35.CrossRef Okamura A, Takeuchi H, Matsuda S, Ogura M, Miyasho T, Nakamura R, et al. Factors affecting cytokine change after esophagectomy for esophageal cancer. Ann Surg Oncol. 2015;22:3130–35.CrossRef
4.
go back to reference Tsujimoto H, Takahata R, Nomura S, Kumano I, Matsumoto Y, Yoshida K, et al. Predictive value of pleural and serum interleukin-6 levels for pneumonia and hypo-oxygenations after esophagectomy. J Surg Res. 2013;182:e61-7.CrossRef Tsujimoto H, Takahata R, Nomura S, Kumano I, Matsumoto Y, Yoshida K, et al. Predictive value of pleural and serum interleukin-6 levels for pneumonia and hypo-oxygenations after esophagectomy. J Surg Res. 2013;182:e61-7.CrossRef
5.
go back to reference Tsujimoto H, Ono S, Chochi K, Sugasawa H, Ichikura T, Mochizuki H. Preoperative chemoradiotherapy for esophageal cancer enhances the postoperative systemic inflammatory response. Jpn J Clin Oncol. 2006;36:632–7.CrossRef Tsujimoto H, Ono S, Chochi K, Sugasawa H, Ichikura T, Mochizuki H. Preoperative chemoradiotherapy for esophageal cancer enhances the postoperative systemic inflammatory response. Jpn J Clin Oncol. 2006;36:632–7.CrossRef
6.
go back to reference Aosasa S, Ono S, Mochizuki H, Tsujimoto H, Osada S, Takayama E, et al. Activation of monocytes and endothelial cells depends on the severity of surgical stress. World J Surg. 2000;24:10–6.CrossRef Aosasa S, Ono S, Mochizuki H, Tsujimoto H, Osada S, Takayama E, et al. Activation of monocytes and endothelial cells depends on the severity of surgical stress. World J Surg. 2000;24:10–6.CrossRef
7.
go back to reference Ono S, Aosasa S, Mochizuki H. Effects of a protease inhibitor on reduction of surgical stress in esophagectomy. Am J Surg. 1999;177:78–82.CrossRef Ono S, Aosasa S, Mochizuki H. Effects of a protease inhibitor on reduction of surgical stress in esophagectomy. Am J Surg. 1999;177:78–82.CrossRef
8.
go back to reference Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990;12:1179–86.CrossRef Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990;12:1179–86.CrossRef
9.
go back to reference Otowa Y, Nakamura T, Yamamoto M, Kanaji S, Matsuda Y, Matsuda T, et al. C-reactive protein to albumin ratio is a prognostic factor for patients with cStage II/III esophageal squamous cell cancer. Dis Esophagus. 2017;30:1–5.CrossRef Otowa Y, Nakamura T, Yamamoto M, Kanaji S, Matsuda Y, Matsuda T, et al. C-reactive protein to albumin ratio is a prognostic factor for patients with cStage II/III esophageal squamous cell cancer. Dis Esophagus. 2017;30:1–5.CrossRef
10.
go back to reference Ibuki Y, Hamai Y, Hihara J, Emi M, Taomoto J, Furukawa T, et al. Role of postoperative C-reactive protein levels in predicting prognosis after surgical treatment of esophageal cancer. World J Surg. 2017;41:1558–65.CrossRef Ibuki Y, Hamai Y, Hihara J, Emi M, Taomoto J, Furukawa T, et al. Role of postoperative C-reactive protein levels in predicting prognosis after surgical treatment of esophageal cancer. World J Surg. 2017;41:1558–65.CrossRef
11.
go back to reference Nozoe T, Saeki H, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg. 2001;182:197–201.CrossRef Nozoe T, Saeki H, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg. 2001;182:197–201.CrossRef
12.
go back to reference Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Aoki T, et al. Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol. 2003;83:248–52.CrossRef Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Aoki T, et al. Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol. 2003;83:248–52.CrossRef
13.
go back to reference Park JK, Kim JJ, Moon SW. C-reactive protein for the early prediction of anastomotic leak after esophagectomy in both neoadjuvant and non-adjuvant therapy case: a propensity score matching analysis. J Thorac Dis. 2017;9:3693–702.CrossRef Park JK, Kim JJ, Moon SW. C-reactive protein for the early prediction of anastomotic leak after esophagectomy in both neoadjuvant and non-adjuvant therapy case: a propensity score matching analysis. J Thorac Dis. 2017;9:3693–702.CrossRef
14.
go back to reference Kano K, Aoyama T, Nakajima T, Maezawa Y, Hayashi T, Yamada T, et al. Prediction of postoperative inflammatory complications after esophageal cancer surgery based on early changes in the C-reactive protein level in patients who received perioperative steroid therapy and enhanced recovery after surgery care: a retrospective analysis. BMC Cancer. 2017;17:812.CrossRef Kano K, Aoyama T, Nakajima T, Maezawa Y, Hayashi T, Yamada T, et al. Prediction of postoperative inflammatory complications after esophageal cancer surgery based on early changes in the C-reactive protein level in patients who received perioperative steroid therapy and enhanced recovery after surgery care: a retrospective analysis. BMC Cancer. 2017;17:812.CrossRef
15.
go back to reference Wang CS, Sun CF. C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J. 2009;32:471–82.PubMed Wang CS, Sun CF. C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J. 2009;32:471–82.PubMed
16.
go back to reference Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumors. 7th ed. Chichester: Wiley; 2009. Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumors. 7th ed. Chichester: Wiley; 2009.
17.
go back to reference Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRef Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRef
18.
go back to reference Japanese Society for Esophageal Diseases. Guidelines for clinical and pathologic studies on carcinoma of the esophagus, ninth edition: preface, general principles, part I. Esophagus. 2004;1:61–88. Japanese Society for Esophageal Diseases. Guidelines for clinical and pathologic studies on carcinoma of the esophagus, ninth edition: preface, general principles, part I. Esophagus. 2004;1:61–88.
19.
go back to reference Otowa Y, Nakamura T, Takiguchi G, Tomono A, Yamamoto M, Kanaji S, et al. Changes in modified Glasgow prognostic score after neoadjuvant chemotherapy is a prognostic factor in clinical stage II/III esophageal cancer. Dis Esophagus. 2016;29:146–51.CrossRef Otowa Y, Nakamura T, Takiguchi G, Tomono A, Yamamoto M, Kanaji S, et al. Changes in modified Glasgow prognostic score after neoadjuvant chemotherapy is a prognostic factor in clinical stage II/III esophageal cancer. Dis Esophagus. 2016;29:146–51.CrossRef
20.
go back to reference Sato N, Endo S, Kimura Y, Ikeda K, Aoki K, Iwaya T, et al. Influence of a human protease inhibitor on surgical stress induced immunosuppression. Dig Surg. 2002;19:300–5.CrossRef Sato N, Endo S, Kimura Y, Ikeda K, Aoki K, Iwaya T, et al. Influence of a human protease inhibitor on surgical stress induced immunosuppression. Dig Surg. 2002;19:300–5.CrossRef
21.
go back to reference Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine. 1992;4:361–8.CrossRef Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine. 1992;4:361–8.CrossRef
22.
go back to reference Jones SA, Novick D, Horiuchi S, Yamamoto N, Szalai AJ, Fuller GM. C-reactive protein: a physiological activator of interleukin 6 receptor shedding. J Exp Med. 1999;189:599–604.CrossRef Jones SA, Novick D, Horiuchi S, Yamamoto N, Szalai AJ, Fuller GM. C-reactive protein: a physiological activator of interleukin 6 receptor shedding. J Exp Med. 1999;189:599–604.CrossRef
23.
go back to reference Biere SS, van Berge Henegouwen MI, Maas KW, Bonavina L, Rosman C, Garcia JR, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet. 2012;z379:1887–92.CrossRef Biere SS, van Berge Henegouwen MI, Maas KW, Bonavina L, Rosman C, Garcia JR, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet. 2012;z379:1887–92.CrossRef
24.
go back to reference Ahmadi N, Crnic A, Seely AJ, Sundaresan SR, Villeneuve PJ, Maziak DE, et al. Impact of surgical approach on perioperative and long-term outcomes following esophagectomy for esophageal cancer. Surg Endosc. 2018;32:1892–900.CrossRef Ahmadi N, Crnic A, Seely AJ, Sundaresan SR, Villeneuve PJ, Maziak DE, et al. Impact of surgical approach on perioperative and long-term outcomes following esophagectomy for esophageal cancer. Surg Endosc. 2018;32:1892–900.CrossRef
25.
go back to reference Kanekiyo S, Takeda S, Tsutsui M, Nishiyama M, Kitahara M, Shindo Y, et al. Low invasiveness of thoracoscopic esophagectomy in the prone position for esophageal cancer: a propensity score-matched comparison of operative approaches between thoracoscopic and open esophagectomy. Surg Endosc. 2018;32:1945–53.CrossRef Kanekiyo S, Takeda S, Tsutsui M, Nishiyama M, Kitahara M, Shindo Y, et al. Low invasiveness of thoracoscopic esophagectomy in the prone position for esophageal cancer: a propensity score-matched comparison of operative approaches between thoracoscopic and open esophagectomy. Surg Endosc. 2018;32:1945–53.CrossRef
26.
go back to reference Sato N, Koeda K, Ikeda K, Kimura Y, Aoki K, Iwaya T, et al. Randomized study of the benefits of preoperative corticosteroid administration on the postoperative morbidity and cytokine response in patients undergoing surgery for esophageal cancer. Ann Surg. 2002;236:184–90.CrossRef Sato N, Koeda K, Ikeda K, Kimura Y, Aoki K, Iwaya T, et al. Randomized study of the benefits of preoperative corticosteroid administration on the postoperative morbidity and cytokine response in patients undergoing surgery for esophageal cancer. Ann Surg. 2002;236:184–90.CrossRef
27.
go back to reference Engelman E, Maeyens C. Effect of preoperative single-dose corticosteroid administration on postoperative morbidity following esophagectomy. J Gastrointest Surg. 2010;14:788–804.CrossRef Engelman E, Maeyens C. Effect of preoperative single-dose corticosteroid administration on postoperative morbidity following esophagectomy. J Gastrointest Surg. 2010;14:788–804.CrossRef
28.
go back to reference Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol. 2003;10:972–92.CrossRef Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol. 2003;10:972–92.CrossRef
Metadata
Title
Meaning of C-reactive protein around esophagectomy for cStage III esophageal cancer
Authors
Yasunori Otowa
Tetsu Nakamura
Yuta Yamazaki
Gosuke Takiguchi
Akio Nakagawa
Masashi Yamamoto
Shingo Kanaji
Takeru Matsuda
Taro Oshikiri
Satoshi Suzuki
Yoshihiro Kakeji
Publication date
01-01-2019
Publisher
Springer Singapore
Published in
Surgery Today / Issue 1/2019
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-018-1706-z

Other articles of this Issue 1/2019

Surgery Today 1/2019 Go to the issue